Latest filing published 13 Jul 2026 for Esperion Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +58.8%Entry US$1.36 · Close at T+365 US$2.16
- -78.1%Entry US$6.36 · Close at T+365 US$1.39
- -81.2%Entry US$36.20 · Close at T+365 US$6.80
- +16.1%Entry US$331.50 · Close at T+365 US$385.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
J. Martin Carroll: trading record in brief
J. Martin Carroll (board member) discloses dealings in 6 companies, chiefly Mallinckrodt plc, Catalent, Inc. and Esperion Therapeutics, Inc. The record holds 64 filings, for trades running from 9 May 2013 to 13 July 2026.
In open-market terms, that means 8 purchases worth €472k on one side and 2 sales worth €14k on the other. Netting one side against the other leaves €458k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 35 share grants and 1 option exercise.
In size, the median ticket on the buying side is €65k. 3 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 4 purchases show a median change of +2.5%, with the price up in 50% of them. These figures describe past trades and do not predict future prices.
The record was last updated on 13 July 2026 with a transaction in Esperion Therapeutics, Inc. The last insider purchase was made public on 11 May 2023, 1,277 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to J. Martin Carroll
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 177,523 sharesCommon StockSEC:0001628280-26-048012:0
- 79,873 shares0Common StockSEC:0001628280-26-039520:0
- 33,000 shares0Common StockSEC:0001628280-25-028830:0
- 32,734 sharesCommon StockSEC:0000950170-24-137708:0
- 4,663 shares0Common StockSEC:0001596783-24-000101:0
- 23,000 shares0Common StockSEC:0001628280-24-025223:0
- 6,993 shares0Common StockSEC:0001596783-23-000159:0
- 555 shares0Common StockSEC:0001596783-23-000044:0
- 5,150 shares0Common StockSEC:0001628280-23-022457:0
- 23,091 shares@ US$1.5746.9% of flowCommon StockSEC:0001628280-23-017563:1Canonical exit: 9 Aug 2023 (T+90)
- 8,409 shares@ US$1.491930.4% of flowCommon StockSEC:0001628280-23-017563:0Canonical exit: 8 Aug 2023 (T+90)
- 4,149 shares0Common StockSEC:0001596783-22-000163:0
- 5,000 shares@ US$5.635969.6% of flowCommon StockSEC:0001628280-22-016165:0Canonical exit: 31 Aug 2022 (T+90)
- 3,136 shares@ US$134.1244.1% of flowCommon StockSEC:0001596783-21-000194:2
- 3,136 shares0Common StockSEC:0001596783-21-000194:1
- 3,136 shares0Common StockSEC:0001596783-21-000194:0
- 1,402 shares0Common StockSEC:0001596783-21-000169:0
- 96,864 sharesCommon StockSEC:0001387131-21-008434:0
- 10,667 shares@ US$0.40070.7% of flowOrdinary SharesSEC:0000950138-21-000222:0
- 31,398 shares@ US$0.40072.1% of flowOrdinary SharesSEC:0000950138-21-000222:1
- 2,125 shares0Common StockSEC:0001596783-20-000210:0
- 661 shares0Common StockSEC:0001596783-20-000140:0
- 8,729 shares@ US$2.96100.0% of flowOrdinary SharesSEC:0000950138-20-000255:0
- 3,600 shares@ US$72.2950.0% of flowCommon StockSEC:0001596783-20-000058:2
- 3,600 shares0Common StockSEC:0001596783-20-000058:0
25 of 59 declarations
